{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:05:36Z","timestamp":1789423536470,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009323","name":"Animal Free Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V009494\/1"],"award-info":[{"award-number":["MR\/V009494\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An important role for phenotype switching has been demonstrated in metastasis and therapeutic resistance of both melanoma and epithelial tumours. Phenotype switching in epithelial tumours is driven by a minority cancer stem cell (CSC) sub-population with lineage plasticity, but such a sub-population has not been identified in melanoma. We investigated whether cell surface markers used to identify CSCs in epithelial tumours could identify a CSC sub-population with lineage plasticity in melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified a CD24\n                      <jats:sup>+<\/jats:sup>\n                      CD271\n                      <jats:sup>+<\/jats:sup>\n                      minority sub-population in melanoma that possesses the stem cell characteristics of lineage plasticity and self-renewal. This population displayed hybrid characteristics, combining the attributes of discrete CD24\n                      <jats:sup>+<\/jats:sup>\n                      CD271\n                      <jats:sup>-<\/jats:sup>\n                      and CD24\n                      <jats:sup>-<\/jats:sup>\n                      CD271\n                      <jats:sup>+<\/jats:sup>\n                      cellular sub-populations but with heightened sphere formation, lineage plasticity, migratory ability and drug resistance over its single-marker counterparts. CD24\n                      <jats:sup>+<\/jats:sup>\n                      CD271\n                      <jats:sup>-<\/jats:sup>\n                      and CD24\n                      <jats:sup>+<\/jats:sup>\n                      CD271\n                      <jats:sup>+<\/jats:sup>\n                      stem cell sub-populations were observed in 10% of human melanomas, mainly at the invasive front. They were also found in human tumour scRNAseq datasets, where they expressed genes associated with stem cells and therapeutic resistance. The CD24\n                      <jats:sup>-<\/jats:sup>\n                      CD271\n                      <jats:sup>+<\/jats:sup>\n                      sub-population, on the other hand, shared expression of epithelial-mesenchymal transition (EMT) genes with the CD24\n                      <jats:sup>+<\/jats:sup>\n                      CD271\n                      <jats:sup>+<\/jats:sup>\n                      sub-population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The lack of CD24\n                      <jats:sup>+<\/jats:sup>\n                      CD271\n                      <jats:sup>-<\/jats:sup>\n                      and CD24\n                      <jats:sup>+<\/jats:sup>\n                      CD271\n                      <jats:sup>+<\/jats:sup>\n                      stem cells in the majority of human melanoma specimens led us to conclude that they may be dispensable for melanoma progression. Nevertheless, the enhanced sphere formation, lineage plasticity, migratory ability and drug resistance of the CD24\n                      <jats:sup>+<\/jats:sup>\n                      CD271\n                      <jats:sup>+<\/jats:sup>\n                      sub-population may signal a contextual requirement for these stem cells when melanomas face challenging environments both clinically and in experimental systems.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12915-025-02336-2","type":"journal-article","created":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T23:02:09Z","timestamp":1754262129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A CD24+CD271+ melanoma cancer stem cell possesses hybrid characteristics of its single marker counterparts and promotes invasion and therapeutic resistance"],"prefix":"10.1186","volume":"23","author":[{"given":"Olivia","family":"Knowles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Doldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Hillier-Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Lunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gehad","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Gammon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C.","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Philpott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Harwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Biddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"2336_CR1","unstructured":"American Cancer Society. Cancer facts & figures. Atlanta: The Society. p. volumes."},{"issue":"5","key":"2336_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0092-8674(00)80583-8","volume":"96","author":"SJ Morrison","year":"1999","unstructured":"Morrison SJ, White PM, Zock C, Anderson DJ. Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. Cell. 1999;96(5):737\u201349.","journal-title":"Cell"},{"issue":"15","key":"2336_CR3","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1158\/0008-5472.CAN-11-1059","volume":"71","author":"A Biddle","year":"2011","unstructured":"Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, Emich H, et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res. 2011;71(15):5317\u201326.","journal-title":"Cancer Res"},{"issue":"3","key":"2336_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.devcel.2019.04.010","volume":"49","author":"W Lu","year":"2019","unstructured":"Lu W, Kang Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 2019;49(3):361\u201374.","journal-title":"Dev Cell"},{"issue":"6","key":"2336_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ccr.2012.09.022","volume":"22","author":"JH Tsai","year":"2012","unstructured":"Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell. 2012;22(6):725\u201336.","journal-title":"Cancer Cell"},{"issue":"7842","key":"2336_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41586-020-03046-1","volume":"589","author":"I Pastushenko","year":"2021","unstructured":"Pastushenko I, Mauri F, Song Y, de Cock F, Meeusen B, Swedlund B, et al. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature. 2021;589(7842):448\u201355.","journal-title":"Nature"},{"key":"2336_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ebiom.2016.01.007","volume":"4","author":"A Biddle","year":"2016","unstructured":"Biddle A, Gammon L, Liang X, Costea DE, Mackenzie IC. Phenotypic plasticity determines cancer stem cell therapeutic resistance in oral squamous cell carcinoma. EBioMedicine. 2016;4:138\u201345.","journal-title":"EBioMedicine"},{"issue":"1","key":"2336_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.stemcr.2013.11.009","volume":"2","author":"S Liu","year":"2014","unstructured":"Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports. 2014;2(1):78\u201391.","journal-title":"Stem Cell Reports"},{"issue":"3","key":"2336_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","volume":"1","author":"PC Hermann","year":"2007","unstructured":"Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3):313\u201323.","journal-title":"Cell Stem Cell"},{"issue":"7702","key":"2336_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-018-0040-3","volume":"556","author":"I Pastushenko","year":"2018","unstructured":"Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, et al. Identification of the tumour transition states occurring during EMT. Nature. 2018;556(7702):463\u20138.","journal-title":"Nature"},{"key":"2336_CR11","doi-asserted-by":"publisher","first-page":"e90298","DOI":"10.7554\/eLife.90298","volume":"12","author":"G Youssef","year":"2023","unstructured":"Youssef G, Gammon L, Ambler L, Lunetto S, Scemama A, Cottom H, et al. Disseminating cells in human oral tumours possess an EMT cancer stem cell marker profile that is predictive of metastasis in image-based machine learning. eLife. 2023;12:e90298.","journal-title":"eLife"},{"issue":"19\u201320","key":"2336_CR12","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1101\/gad.329771.119","volume":"33","author":"F Rambow","year":"2019","unstructured":"Rambow F, Marine JC, Goding CR. Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes Dev. 2019;33(19\u201320):1295\u2013318.","journal-title":"Genes Dev"},{"issue":"24","key":"2336_CR13","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1101\/gad.406406","volume":"20","author":"S Carreira","year":"2006","unstructured":"Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek KS, et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006;20(24):3426\u201339.","journal-title":"Genes Dev"},{"issue":"10","key":"2336_CR14","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.15252\/emmm.201505971","volume":"8","author":"G Richard","year":"2016","unstructured":"Richard G, Dalle S, Monet MA, Ligier M, Boespflug A, Pommier RM, et al. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. EMBO Mol Med. 2016;8(10):1143\u201361.","journal-title":"EMBO Mol Med"},{"key":"2336_CR15","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1038\/ncomms6712","volume":"5","author":"J M\u00fcller","year":"2014","unstructured":"M\u00fcller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, et al. Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5:5712.","journal-title":"Nat Commun"},{"issue":"1","key":"2336_CR16","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/s41467-017-01573-6","volume":"8","author":"G Restivo","year":"2017","unstructured":"Restivo G, Diener J, Cheng PF, Kiowski G, Bonalli M, Biedermann T, et al. Low neurotrophin receptor CD271 regulates phenotype switching in melanoma. Nat Commun. 2017;8(1):1988.","journal-title":"Nat Commun"},{"issue":"12","key":"2336_CR17","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1038\/jid.2011.218","volume":"131","author":"M Sensi","year":"2011","unstructured":"Sensi M, Catani M, Castellano G, Nicolini G, Alciato F, Tragni G, et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol. 2011;131(12):2448\u201357.","journal-title":"J Invest Dermatol"},{"issue":"7302","key":"2336_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nature09161","volume":"466","author":"AD Boiko","year":"2010","unstructured":"Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466(7302):133\u20137.","journal-title":"Nature"},{"issue":"12","key":"2336_CR19","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1158\/0008-5472.CAN-19-3230","volume":"80","author":"A Patel","year":"2020","unstructured":"Patel A, Garcia LF, Mannella V, Gammon L, Borg TM, Maffucci T, et al. Targeting p63 upregulation abrogates resistance to MAPK inhibitors in melanoma. Cancer Res. 2020;80(12):2676\u201388.","journal-title":"Cancer Res"},{"issue":"7420","key":"2336_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature11538","volume":"490","author":"J Landsberg","year":"2012","unstructured":"Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412\u20136.","journal-title":"Nature"},{"key":"2336_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-1-0716-1205-7_14","volume":"2265","author":"N Mukherjee","year":"2021","unstructured":"Mukherjee N, Lambert KA, Norris DA, Shellman YG. Enrichment of melanoma stem-like cells via sphere assays. Methods Mol Biol. 2021;2265:185\u201399.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"2336_CR22","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jid.2019.07.720","volume":"140","author":"G Zhu","year":"2020","unstructured":"Zhu G, Xu P, Guo S, Yi X, Wang H, Yang Y, et al. Metastatic melanoma cells rely on Sestrin2 to acquire anoikis resistance via detoxifying intracellular ROS. J Invest Dermatol. 2020;140(3):666-75.e2.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2336_CR23","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","volume":"141","author":"T Sato","year":"2011","unstructured":"Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett\u2019s epithelium. Gastroenterology. 2011;141(5):1762\u201372.","journal-title":"Gastroenterology"},{"issue":"6","key":"2336_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00418-017-1606-0","volume":"148","author":"D Murtas","year":"2017","unstructured":"Murtas D, Maxia C, Diana A, Pilloni L, Corda C, Minerba L, et al. Role of epithelial-mesenchymal transition involved molecules in the progression of cutaneous melanoma. Histochem Cell Biol. 2017;148(6):639\u201349.","journal-title":"Histochem Cell Biol"},{"issue":"1","key":"2336_CR25","doi-asserted-by":"publisher","first-page":"7696","DOI":"10.1038\/s41598-019-42773-y","volume":"9","author":"FV Filipp","year":"2019","unstructured":"Filipp FV, Li C, Boiko AD. CD271 is a molecular switch with divergent roles in melanoma and melanocyte development. Sci Rep. 2019;9(1):7696.","journal-title":"Sci Rep"},{"issue":"2","key":"2336_CR26","doi-asserted-by":"publisher","first-page":"e17083","DOI":"10.1371\/journal.pone.0017083","volume":"6","author":"E Katz","year":"2011","unstructured":"Katz E, Dubois-Marshall S, Sims AH, Gautier P, Caldwell H, Meehan RR, et al. An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer. PLoS One. 2011;6(2):e17083.","journal-title":"PLoS One"},{"issue":"2","key":"2336_CR27","first-page":"313","volume":"1871","author":"I Kozar","year":"2019","unstructured":"Kozar I, Margue C, Rothengatter S, Haan C, Kreis S. Many ways to resistance: how melanoma cells evade targeted therapies. Biochimica et Biophysica Acta (BBA). 2019;1871(2):313\u201322.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"9","key":"2336_CR28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/jnci\/djn123","volume":"100","author":"X Li","year":"2008","unstructured":"Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100(9):672\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"2336_CR29","doi-asserted-by":"publisher","first-page":"5416923","DOI":"10.1155\/2018\/5416923","volume":"2018","author":"LTH Phi","year":"2018","unstructured":"Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018;2018:5416923.","journal-title":"Stem Cells Int"},{"key":"2336_CR30","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1038\/ncomms7139","volume":"6","author":"A Goldman","year":"2015","unstructured":"Goldman A, Majumder B, Dhawan A, Ravi S, Goldman D, Kohandel M, et al. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nat Commun. 2015;6:6139.","journal-title":"Nat Commun"},{"issue":"4","key":"2336_CR31","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.cell.2018.12.038","volume":"176","author":"M Georgouli","year":"2019","unstructured":"Georgouli M, Herraiz C, Crosas-Molist E, Fanshawe B, Maiques O, Perdrix A, et al. Regional activation of myosin II in cancer cells drives tumor progression via a secretory cross-talk with the immune microenvironment. Cell. 2019;176(4):757-74 e23.","journal-title":"Cell"},{"issue":"22","key":"2336_CR32","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.cub.2015.09.054","volume":"25","author":"G Cantelli","year":"2015","unstructured":"Cantelli G, Orgaz JL, Rodriguez-Hernandez I, Karagiannis P, Maiques O, Matias-Guiu X, et al. TGF-beta-induced transcription sustains amoeboid melanoma migration and dissemination. Curr Biol. 2015;25(22):2899\u2013914.","journal-title":"Curr Biol"},{"issue":"16","key":"2336_CR33","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622\u201334.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2336_CR34","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell. 2018;175(4):984-97.e24.","journal-title":"Cell"},{"key":"2336_CR35","unstructured":"Single-cell RNA-seq of melanoma ecosystems reveals sources of T cell exclusion linked to immunotherapy clinical outcomes. Broad Single Cell Portal; 2018. https:\/\/singlecell.broadinstitute.org\/single_cell\/study\/SCP109\/melanoma-immunotherapy-resistance#study-summary."},{"issue":"5","key":"2336_CR36","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2010.10.012","volume":"18","author":"E Quintana","year":"2010","unstructured":"Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 2010;18(5):510\u201323.","journal-title":"Cancer Cell"},{"key":"2336_CR37","unstructured":"scRNA-seq data of malignant cells from human melanoma metastatic biopsies. VIB-KU Leuven Center for Cancer Biology; 2024. https:\/\/marine-lab.shinyapps.io\/Human_melanoma_scRNASeq\/."},{"issue":"4","key":"2336_CR38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccr.2013.08.018","volume":"24","author":"J Caramel","year":"2013","unstructured":"Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 2013;24(4):466\u201380.","journal-title":"Cancer Cell"},{"issue":"12","key":"2336_CR39","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1002\/ijc.31609","volume":"143","author":"L H\u00fcser","year":"2018","unstructured":"H\u00fcser L, Sachindra S, Granados K, Federico A, Larrib\u00e8re L, Novak D, et al. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma. Int J Cancer. 2018;143(12):3131\u201342.","journal-title":"Int J Cancer"},{"issue":"2","key":"2336_CR40","doi-asserted-by":"publisher","first-page":"e001037","DOI":"10.1136\/jitc-2020-001037","volume":"8","author":"R Wu","year":"2020","unstructured":"Wu R, Wang C, Li Z, Xiao J, Li C, Wang X, et al. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. J Immunother Cancer. 2020;8(2):e001037.","journal-title":"J Immunother Cancer"},{"issue":"38","key":"2336_CR41","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1038\/onc.2014.71","volume":"33","author":"R Santini","year":"2014","unstructured":"Santini R, Pietrobono S, Pandolfi S, Montagnani V, D\u2019Amico M, Penachioni JY, et al. SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells. Oncogene. 2014;33(38):4697\u2013708.","journal-title":"Oncogene"},{"issue":"31","key":"2336_CR42","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.1038\/onc.2017.55","volume":"36","author":"SM Schaefer","year":"2017","unstructured":"Schaefer SM, Segalada C, Cheng PF, Bonalli M, Parfejevs V, Levesque MP, et al. Sox2 is dispensable for primary melanoma and metastasis formation. Oncogene. 2017;36(31):4516\u201324.","journal-title":"Oncogene"},{"issue":"12","key":"2336_CR43","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1038\/s44321-024-00161-8","volume":"16","author":"M Fournier","year":"2024","unstructured":"Fournier M, Javary J, Roh V, Fournier N, Radtke F. Reciprocal inhibition of NOTCH and SOX2 shapes tumor cell plasticity and therapeutic escape in triple-negative breast cancer. EMBO Mol Med. 2024;16(12):3184\u2013217.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"2336_CR44","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41467-019-10100-8","volume":"10","author":"V Prakash","year":"2019","unstructured":"Prakash V, Carson BB, Feenstra JM, Dass RA, Sekyrova P, Hoshino A, et al. Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease. Nat Commun. 2019;10(1):2110.","journal-title":"Nat Commun"},{"issue":"10","key":"2336_CR45","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1158\/1541-7786.MCR-09-0191","volume":"7","author":"JH Lee","year":"2009","unstructured":"Lee JH, Suk J, Park J, Kim SB, Kwak SS, Kim JW, et al. Notch signal activates hypoxia pathway through HES1-dependent SRC\/signal transducers and activators of transcription 3 pathway. Mol Cancer Res. 2009;7(10):1663\u201371.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"2336_CR46","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ncb1691","volume":"10","author":"MH Yang","year":"2008","unstructured":"Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol. 2008;10(3):295\u2013305.","journal-title":"Nat Cell Biol"},{"issue":"11","key":"2336_CR47","doi-asserted-by":"publisher","first-page":"e49865","DOI":"10.1371\/journal.pone.0049865","volume":"7","author":"M Gschaider","year":"2012","unstructured":"Gschaider M, Neumann F, Peters B, Lenz F, Cibena M, Goiser M, et al. An attempt at a molecular prediction of metastasis in patients with primary cutaneous melanoma. PLoS One. 2012;7(11):e49865.","journal-title":"PLoS One"},{"issue":"11","key":"2336_CR48","first-page":"4337","volume":"7","author":"MR Tang","year":"2014","unstructured":"Tang MR, Wang YX, Guo S, Han SY, Li HH, Jin SF. CD24 expression predicts poor prognosis for patients with cutaneous malignant melanoma. Int J Clin Exp Med. 2014;7(11):4337\u201341.","journal-title":"Int J Clin Exp Med"},{"issue":"6","key":"2336_CR49","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ccr.2012.03.048","volume":"21","author":"W Liu","year":"2012","unstructured":"Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, et al. LKB1\/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell. 2012;21(6):751\u201364.","journal-title":"Cancer Cell"},{"issue":"21","key":"2336_CR50","doi-asserted-by":"publisher","first-page":"7892","DOI":"10.3390\/ijms21217892","volume":"21","author":"CH Weng","year":"2020","unstructured":"Weng CH, Wu CS, Wu JC, Kung ML, Wu MH, Tai MH. Cisplatin-induced giant cells formation is involved in chemoresistance of melanoma cells. Int J Mol Sci. 2020;21(21):7892.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"2336_CR51","doi-asserted-by":"publisher","first-page":"10783","DOI":"10.1158\/0008-5472.CAN-05-0619","volume":"65","author":"P Baumann","year":"2005","unstructured":"Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 2005;65(23):10783\u201393.","journal-title":"Cancer Res"},{"issue":"7577","key":"2336_CR52","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature15726","volume":"527","author":"E Piskounova","year":"2015","unstructured":"Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015;527(7577):186\u201391.","journal-title":"Nature"},{"issue":"7823","key":"2336_CR53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2623-z","volume":"585","author":"JM Ubellacker","year":"2020","unstructured":"Ubellacker JM, Tasdogan A, Ramesh V, Shen B, Mitchell EC, Martin-Sandoval MS, et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature. 2020;585(7823):113\u20138.","journal-title":"Nature"},{"issue":"4","key":"2336_CR54","first-page":"913","volume":"72","author":"JM Kozlowski","year":"1984","unstructured":"Kozlowski JM, Hart IR, Fidler IJ, Hanna N. A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst. 1984;72(4):913\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"35","key":"2336_CR55","doi-asserted-by":"publisher","first-page":"5968","DOI":"10.1038\/sj.onc.1207780","volume":"23","author":"M Daniotti","year":"2004","unstructured":"Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene. 2004;23(35):5968\u201377.","journal-title":"Oncogene"},{"issue":"1","key":"2336_CR56","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cell.2023.11.037","volume":"187","author":"J Pozniak","year":"2024","unstructured":"Pozniak J, Pedri D, Landeloos E, Van Herck Y, Antoranz A, Vanwynsberghe L, et al. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell. 2024;187(1):166-83.e25.","journal-title":"Cell"}],"container-title":["BMC Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12915-025-02336-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12915-025-02336-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12915-025-02336-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:20:36Z","timestamp":1757337636000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiol.biomedcentral.com\/articles\/10.1186\/s12915-025-02336-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2336"],"URL":"https:\/\/doi.org\/10.1186\/s12915-025-02336-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.06.07.544036","asserted-by":"object"}]},"ISSN":["1741-7007"],"issn-type":[{"value":"1741-7007","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the East London Research Ethics Committee (project 07\/Q0604\/23). Consent was obtained from all patients in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}